Teva's generic Pravachol barred

Teva is currently in patent litigation on Pantoprazole. Final approval was expected by August 2007.

By SETH FREEDMAN
April 25, 2006 07:49

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Teva Pharmaceuticals said Friday a US federal appeals court had barred the company from selling its generic version of Pravachol, until the court has considered the outstanding dispute, which centers on rival generic drug maker Apotex's contention that exclusivity to manufacture the cholesterol drug should be granted to the Canadian firm, rather than to Teva. Separately, Teva said it received tentative FDA approval for its generic version of Wyeth's Protonix tablets. Marketed under the name Pantoprazole, Teva's version of Protonix will be used to treat erosive esophagitis and hypersecretory conditions. US brand sales of the drug were about $2.4 billion in 2005. Teva is currently in patent litigation on Pantoprazole. Final approval was expected by August 2007.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS